Dr. Ezra Cohen on the Early Halting of the CheckMate-141 Trial
Cohen says while the data from the study looking at nivolumab has not been released yet, the halting of the trial due it having met its primary OS endpoint likely means good news.
Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the early halting of the CheckMate-141 trial. The trial is looking at nivolumab (Opdivo) and its ability to boost overall survival (OS) in patients with in platinum-refractory squamous cell carcinoma of the head and neck (SCCHN).
Cohen says while the data from the study has not been released yet, the halting of the trial due it having met its primary overall survival (OS) endpoint likely means good news. He adds that considering the standard therapies in the current second-line setting currently have a "dismal" progression-free survival and OS for patients, the addition of nivolumab would greatly benefit patients.
According to a recent press release from the drug's manufacturer Bristol-Myers Squibb, the study was stopped after a panel determined the primary endpoint was met with nivolumab versus investigator's choice of cetuximab, methotrexate, or docetaxel.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
Neoadjuvant Pembro Plus Chemo Shows EFS Benefit at 5-Years in TNBC
November 13th 2023In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.
Read More
